Results 91 to 100 of about 38,272 (314)

Implementation of guideline‐recommended medical therapy for patients with heart failure in Europe

ESC Heart Failure, Volume 12, Issue 2, Page 790-798, April 2025.
Abstract Physicians' adherence to guideline‐recommended heart failure (HF) treatment remains suboptimal, especially regarding the target doses. In particular, there is evidence that non‐cardiologists are less compliant with HF guideline recommendations. This is likely to have a detrimental impact on patients' survival, readmissions and quality of life.
Maurizio Volterrani, Petar Seferovic, Gianluigi Savarese, Ilaria Spoletini, Egidio Imbalzano, Antoni Bayes‐Genis, Ewa Jankowska, Michele Senni, Marco Metra, Ovidiu Chioncel, Andrew J. S. Coats, Giuseppe M. C. Rosano   +11 more
wiley   +1 more source

Effect of sodium-glucose co-transporter 2 inhibitor on contrast-induced acute kidney injury and prognosis in type 2 diabetes patients undergoing percutaneous coronary intervention

Frontiers in Medicine
IntroductionContrast-induced acute kidney injury (CIAKI) is a common and serious complication following contrast administration in patients undergoing percutaneous coronary intervention (PCI).
Shicheng Yang, Huifang Hao, Xiufeng Zhai, Peng Zhang, Naikuan Fu   +4 more
doaj   +1 more source

Dapagliflozin Attenuates Hyperglycemia Related Osteoporosis in ZDF Rats by Alleviating Hypercalciuria

Frontiers in Endocrinology, 2019
Recent studies showed that in patients with type 2 diabetes mellitus (T2DM), Sodium-dependent glucose transporters 2 inhibitor (SGLT2I) may cause potential adverse effects on skeleton such as increasing the risk of fracture.
Ji-Yu Wang, Yan-Zhen Cheng, Shuang-Li Yang, Shuang-Li Yang, Min An, Hua Zhang, Hong Chen, Li Yang   +7 more
doaj   +1 more source

Canagliflozin: A Review in Type 2 Diabetes. [PDF]

, 2017
peer reviewedCanagliflozin (Invokana(R)) is a sodium-glucose co-transporter-2 (SGLT2) inhibitor indicated in various countries worldwide for the once-daily oral treatment of type 2 diabetes (T2D).
Deeks, Emma D., Scheen, André
core   +2 more sources

Dapagliflozin and Mode of Death in Heart Failure With Improved Ejection Fraction

JAMA cardiology
Key Points Question What is the mode of death and the association of dapagliflozin with cause-specific death in patients with heart failure with improved ejection fraction (HFimpEF)?
O. Vardeny, A. Desai, P. Jhund, J. Fang, B. Claggett, Rudolf A. de Boer, Adrian F Hernandez, S. Inzucchi, Mikhail N. Kosiborod, C. Lam, F. Martinez, Sanjiv J. Shah, Finnian R. Mc Causland, M. C. Petrie, M. Vaduganathan, J. McMurray, Scott D. Solomon   +16 more
semanticscholar   +1 more source

Projecting the benefit of vericiguat in PARADIGM‐HF and DAPA‐HF populations: Insights from the VICTORIA trial

ESC Heart Failure, Volume 12, Issue 2, Page 1479-1484, April 2025.
Abstract Aims The VICTORIA trial demonstrated a significant reduction in the primary composite outcome of heart failure (HF) hospitalization or cardiovascular death with vericiguat relative to placebo in high‐risk HF. This study aimed to contextualize treatment effects of vericiguat in populations with varying risk profiles simulated from the PARADIGM ...
Veraprapas Kittipibul, Robert J. Mentz, Rebecca Young, Javed Butler, Justin A. Ezekowitz, Carolyn S.P. Lam, Piotr Ponikowski, Adriaan Voors, Stefano Corda, Ciaran McMullan, Christopher M. O'Connor, Kevin J. Anstrom, Paul W. Armstrong, for the VICTORIA Study Group   +13 more
wiley   +1 more source

The effect of dapagliflozin on glycaemic control and other cardiovascular disease risk factors in type 2 diabetes mellitus:a real-world observational study [PDF]

, 2019
Aims/hypothesis: Dapagliflozin, a sodium–glucose cotransporter 2 (SGLT2) inhibitor, is indicated for improving glycaemic control in type 2 diabetes mellitus.
, Blackbourn, Luke A. K., Brierley, Liam, Caparrotta, Thomas M., Colhoun, Helen M., Leese, Graham, McCrimmon, Rory, McGurnaghan, Stuart J., McKeigue, Paul M., McKnight, John A., Pearson, Ewan, Petrie, John R., Sattar, Naveed, Wild, Sarah H.   +13 more
core   +5 more sources

Balcinrenone plus dapagliflozin in patients with heart failure and chronic kidney disease: Results from the phase 2b MIRACLE trial

European Journal of Heart Failure
Many patients with heart failure (HF) have chronic kidney disease (CKD) and may not tolerate mineralocorticoid receptor antagonists. We investigated the efficacy and safety of the novel mineralocorticoid receptor modulator balcinrenone in combination ...
C. S. Lam, L. Køber, K. Kuwahara, Lars H. Lund, P. Mark, Linda G Mellbin, Morten Schou, P. Ely Pizzato, Anders Gabrielsen, S. Gasparyan, Alessandro Ghiretti, Judith Hartleib‐Geschwindner, Greggory J. Housler, Paolo Fanti, M. Leonsson-Zachrisson, J. McMurray, Scott D. Solomon   +16 more
semanticscholar   +1 more source

Effects of sodium–glucose co‐transporter inhibitors on individual clinical endpoints and quality of life

ESC Heart Failure, Volume 12, Issue 2, Page 1271-1282, April 2025.
Effects of SGLTi on Individual Clinical Endpoints and Quality‐of‐Life: outcome from randomized data. Abstract Aims Sodium–glucose co‐transporter inhibitors (SGLTis) have cardiovascular protective effects. We aimed to assess the effects of SGLTis on individual hard clinical endpoints and quality of life (QoL) in patients with cardiovascular risk factors.
Jia Liao, Yang Chen, Zhiyu Ling, Helmut Pürerfellner, Martin Martinek, Michael Derndorfer, Johannes Niel, Ramin Ebrahimi, Matthias Heukäufer, Sarah Janschel, Davide Di Vece, Klaus Empen, Astrid Hummel, Bishwas Chamling, Piotr Futyma, Fahim Ebrahimi, Márcio G. Kiuchi, Shaowen Liu, Yuehui Yin, Alexandra Schratter, Willem‐Jan Acou, Philipp Sommer, Boris Schmidt, Julian K. R. Chun, Christian Meyer, Marcus Dörr, Christian Templin, Shaojie Chen   +27 more
wiley   +1 more source

IL RENE COME NUOVO TARGET DI DI FARMACI ANTIDIABETICI:INIBITORI DI SGLT2 [PDF]

, 2015
IL DIABETE DI TIPO 2 RAPPRESENTA UNA DELLE PATOLOGIE A PIù AMPIO E PROGRESSIVO INCREMENTO NELLA POPOLAZIONE MONDIALE. LA RICERCA DI NUOVI FARMACI E' PERTANTO UN'IMPELLENTE NECESSITA'.
SHTJEFNI, ELONA
core